济南男龟头敏感怎么办济南龟头分泌物绿色,济南市治前列腺的医院哪个好,济南睾丸疼痛的原因是什么,济南前列腺好治吗,济南那里医院好男科,济南射精控制不住怎么办,济南尿道口有透明黏液

WASHINGTON, July 18 (Xinhua) -- Exposure to secondhand smoke ( SHS) is associated with increased risk of hearing loss among adolescents, according to a report in the July issue of Archives of Otolaryngology -- Head and Neck Surgery.Among U.S. children, approximately 60 percent are exposed to SHS, according to background information in the article. Studies have associated exposure to secondhand smoke prenatally or during childhood with various health conditions, from low birth weight and respiratory infections to behavioral problems and otitis media. Children exposed to SHS are more likely to develop recurrent otitis media, the authors note. "Secondhand smoke may also have the potential to have an impact on auditory development, leading to sensorineural hearing loss (SNHL)," they add.Anil Lalwani and colleagues from New York University Langone Medical Center examined the risk factors for SNHL, including SHS, among adolescents, stratified by demographic groups. They included 1,533 individuals from 12 years to 19 years of age who participated in the National Health and Nutrition Examination Survey from 2005 to 2006.Participants were interviewed about their health status and family medical history, exposure to SHS, and self-recognition of hearing impairment. In addition, they underwent a physical examination, including blood testing for cotinine (a by-product of nicotine exposure), and hearing tests.Compared with teens who had no SHS exposure, those who were exposed to secondhand smoke exhibited higher rates of low- and high-frequency hearing loss. The rate of hearing loss appeared to be cumulative, increasing with the level of cotinine detected by blood tests. The results also demonstrated that more than 80 percent of participants with hearing loss did not realize they had impairment.As hearing loss early in life can cause problems with development and functioning, the authors suggest that these results have "significant implications for public health in the United States."They note that most adolescents do not receive screening for hearing loss in the absence of risk factors.If further studies replicate these results, they state, SHS could be considered one such risk factor.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

UNITED NATIONS, June 9 (Xinhua) -- Partners from UN agencies and governments, as well as civil society and the private sector gathered here Thursday to launch "Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive.""Governments and foundations that support this plan are saying: we treasure all life equally," said UN Secretary-General Ban Ki- moon, who spoke at the event. "We give all people the best possible chance. We provide health care to all who need it."This new plan, which was formulated by a Global Task Team of more than 30 governments and 50 international and national organizations, aims to bring the number of new HIV infections in children to zero by the middle of the decade and help their mothers survive.The launch of Countdown to Zero came on the sidelines of the UN High-Level Meeting on AIDS, which runs from June 8-10, and has been an opportunity for participants to take stock of gains made in combating the disease and to agree on a declaration that will direct the actions of member states to prevent and treat HIV/AIDS over the next five years.Ban told the audience at the launch that history has proven that it is possible to make great strides in fighting HIV/AIDS, with the right amount of effort and coordination."Let us not forget that some regions have nearly achieved no new infections from mother to child," he said. "If we push hard, as we have committed today, with your continued help and with the will to do what is right for the world, we can spread this success to mothers everywhere."According to the Joint UN Program on HIV/AIDS (UNAIDS), the rate of HIV/AIDS transmission from mother to child was been reduced by 26 percent from 2001 to 2009.Former U.S. President Bill Clinton, who spoke at the launch, said that he believes the time to eliminate HIV/AIDS in children is at hand."We are here because we all recognize that the time has finally come to end pediatric AIDS worldwide and we believe we can do it," he said. "We know we have the capacity to produce the medicine, we know that."Clinton emphasized the fact that HIV/AIDS is often prevalent in less developed countries. Sub-Saharan Africa remains the region that has the most HIV/AIDS infected people."There are still too many kids who are born HIV-positive," he said. "Just 22 countries account for 90 percent of those pediatric infections."He said that there are not only moral reasons for wealthier countries to help these nations by investing in their HIV/AIDS responses, but that by doing so they increase their soft power -- influence that utilizes non-coercive measures."I think its important in a world where no one wants to look weak and the military justifiably has a claim on all of our budgets, we not forget that what my secretary-of-state often refers to as soft power issues, they have a bigger impact on our long term security," Clinton said. "I think that accounts in no small measure for the presence of leaders of global corporations here at this meeting today, they know this as well."Collaboration and close coordination of responses to HIV/AIDS, Clinton said, is also essential."There are still too many places where HIV and maternal and child health groups work completely separately," he said. "That dramatically reduces the likelihood that mothers are their babies will receive the full range of care. We simply have to all work together, both within governments and all of those who are trying to help to ensure that mothers get the drugs they should and that their babies are born without the virus."Clinton said that Goodluck Jonathan, president of Nigeria, who gave a statement at the launch as well, is an excellent example of the "strong political leadership and personal commitment" necessary to defeat HIV/AIDS and reach to goals set by the Countdown to Zero plan.In his speech, Jonathan said that Africa is has banded together through the Abuja Declaration, adopted in 2001, which turned attention and resources towards public health problems on the continent, particularly HIV/AIDS."That declaration was to make African countries spend at least 15 percent of their budget on their health sector and a reasonable percentage of this would be geared towards HIV prevention and control," he said.Budgeting shortfalls for fighting HIV/AIDS in Africa must be accounted for, Jonathan said, as African countries must not rely solely on donors to fund their responses."I intend to explore in the coming months in collaboration with colleagues in sub-Saharan Africa an effective and creative funding mechanism to ensure ownership and long terms sustainability of the HIV and AIDS response in Africa," he said.

COPENHAGEN, May 29 (Xinhua) -- The number of confirmed E.coli cases has risen to 11 with at least another eight persons suspected of having the intestinal infection in Denmark, according to Denmark's National Serum Institute on Sunday.Five of the confirmed cases show symptoms of kidney failure which marks an advanced stage of the sickness, the institute said.Danish cucumbers are suspected of helping spread the E. coli bacteria believed to be causing a deadly outbreak of intestinal infection in Denmark and Germany, local media reported Sunday.The Danish cucumbers were mixed in Germany with cucumbers originating in the Netherlands, making it difficult to determine if Danish cucumbers are in fact contaminated.Denmark's Veterinary and Food Administration (DVFA) had earlier said the suspicion against Danish cucumber was "vague", but advised Danish consumers not to eat raw tomatoes, lettuces and cucumbers from Germany, and cucumber from Spain.It is now checking Danish cucumbers for traces of E. coli with results expected on Tuesday.Some Danish retailers have now removed these products from their supermarket shelves. And the Danish branch of fast-food chain McDonald's announced Saturday that it was dropping fresh cucumbers from its menu until further notice.The infection, which is food-borne, can be caused by eating raw or uncooked foods such as vegetables contaminated with the E. coli bacteria.Symptoms of infection include mild fever, bloody diarrhea and vomiting, and can last five to seven days. It can prove fatal in the very young, sick, or elderly.

BERLIN, June 10 (Xinhua) -- The German state of North Rhine-Westphalia said Friday it detected for the first time the deadly E.coli strain o104 on bean sprouts, after they were named the source of the outbreak by Germany's national disease control centre. "According to our knowledge, the bean sprouts are coming from the recent suspicious farm in Bienenbuettel in the state of Lower Saxony," said Johannes Remmel, consumer protection minister.The sprouts were found in an opened package which had been left in a dustbin of a family, living near the city of Bonn. Two of the family members had eaten the sprouts and contracted the E. coli infection in mid-May, he said.A notice warning consumers not to eat raw bean sprouts is seen at a market in Berlin, capital of Germany, June 10, 2011. The German authority said on Friday bean sprouts were probably the source of the E. coli outbreak, which has killed 30 people and infected about 3,000 around the world. Reinhard Burger, president of the Robert Koch Institute (RKI), Germany's national disease control center said the Robert Koch Institute was lifting its warning against eating cucumbers, tomatoes and lettuce but keeping the warning in place for the sprouts."The discovery confirms our current warning against the consumption of bean sprouts. It is therefore becoming increasingly more likely that bean sprouts are the source of the E.coli infections," Remmel said.The news came after Reinhard Burger, President of the Robert Koch Institute (RKI), said in the morning bean sprouts were the source for the outbreak based on a epidemiological investigation."People who ate (bean) sprouts were found nine times more likely to have bloody diarrhoea or other signs of E. coli infection than those who did not," he saidHowever, no sample tests had found the o104 strain on bean sprouts when he announced that conclusion. Laboratory tests have shown Germany made mistakes in identifying the outbreak source on two previous occasions.At the same time, RKI lifted the warning against cucumbers, tomatoes and lettuce."Enjoy lettuce, cucumbers and tomatoes. They are healthy for you," said Andreas Hensel, president of the German Federal Risk Assessment Institute (BFR), which is a co-leader in the action against E. coli.In the city of Hamburg, an epicentre for the disease, farmers protested in the city centre by offering tons of lettuce and cucumbers for free to anyone who wanted them when the news was announced. Suddenly, pedestrians turned from reluctant to eager takers, reported local news agency DPA.